291 results on '"Voest, Emile"'
Search Results
2. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma
3. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
4. Agnostic drug development revisited
5. Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens
6. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)
7. A pan-cancer analysis of the microbiome in metastatic cancer
8. Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics
9. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
10. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
11. Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity
12. Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors
13. RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells
14. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
15. Limited evolution of the actionable metastatic cancer genome under therapeutic pressure
16. Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.
17. Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system
18. Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer
19. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
20. Tumor organoid–T-cell coculture systems
21. When oncologic treatment options outpace the existing evidence: Contributing factors and a path forward
22. Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.
23. Is It Our Duty To Hunt for Pathogenic Mutations?
24. Pan-cancer whole-genome analyses of metastatic solid tumours
25. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
26. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
27. Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery
28. Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE)
29. Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
30. Partner independent fusion gene detection by multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing
31. Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations
32. Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab
33. Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids
34. Cancer patients’ intentions towards receiving unsolicited genetic information obtained using next-generation sequencing
35. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
36. Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)
37. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
38. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
39. Long‐term expanding human airway organoids for disease modeling
40. Precision cancer medicine: Concepts, current practice, and future developments.
41. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases
42. Distinct phosphatases antagonize the p53 response in different phases of the cell cycle
43. Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
44. Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens.
45. Facilitating a culture of responsible and effective sharing of cancer genome data
46. A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies
47. Notch1 regulates angio-supportive bone marrow–derived cells in mice: relevance to chemoresistance
48. Intra‐ and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts
49. Symptoms tell it all: A systematic review of the value of symptom assessment to predict survival in advanced cancer patients
50. Impact of integration of clinical and outpatient units on cancer patient satisfaction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.